Larry Blandford, PharmD—Column Editor

Pharma Insights

How Development of Gene Therapies Impact Decisions on Their Place in Therapy

11/18/2019

Aaron Burke

Gene therapy has sparked significant interest among researchers, health care providers, and patients because it offers the tantalizing possibility of a cure, particularly for rare diseases with a genetic basis. While...

Gene...

11/18/2019

Journal of Clinical Pathways

Pharma Insights

The Challenge With Today’s Value Assessments: Not Evolving With the Evidence

04/16/2019

Larry Blandford, PharmD—Column Editor

The methodologies employed within value assessments, especially by the Institute for Clinical and Economic Review (ICER), primarily measure value through quality-adjusted life-years (QALYs). While also the common...

The...

04/16/2019

Journal of Clinical Pathways

Pharma Insights

What Does New Payer Research on Expected Biosimilar Management Mean to Others?

05/12/2017

Larry Blandford, PharmD—Column Editor

Although the biosimilar era has officially launched, only one agent has entered the market as of April 2017. That would be Zarxio1, approved in March 2015 as a biosimilar for the market-leading granulocyte...

...

05/12/2017

Journal of Clinical Pathways

Pharma Insights

When Medication Price Deflates Perception of Therapeutic Effect

04/11/2016

Larry Blandford, PharmD—Column Editor

Stephen C Carter

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

...

04/11/2016

Journal of Clinical Pathways